DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Lessened by XTX Topco Ltd

XTX Topco Ltd lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 65.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,016 shares of the medical device company's stock after selling 19,088 shares during the quarter. XTX Topco Ltd's holdings in DexCom were worth $779,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Watts Gwilliam & Co. LLC acquired a new position in shares of DexCom in the 4th quarter worth approximately $3,334,000. Congress Asset Management Co. grew its position in shares of DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after acquiring an additional 1,332,522 shares in the last quarter. Janney Montgomery Scott LLC grew its position in shares of DexCom by 2,226.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after acquiring an additional 222,548 shares in the last quarter. First Hawaiian Bank grew its position in shares of DexCom by 556.1% in the 4th quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company's stock worth $1,801,000 after acquiring an additional 19,629 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in shares of DexCom in the 4th quarter worth approximately $5,812,000. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Price Performance

Shares of DXCM traded up $1.72 during midday trading on Wednesday, reaching $68.05. The stock had a trading volume of 1,495,290 shares, compared to its average volume of 4,219,216. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $139.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm's 50 day moving average price is $74.27 and its 200-day moving average price is $76.66. The company has a market capitalization of $26.68 billion, a P/E ratio of 47.59, a P/E/G ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on DXCM shares. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and raised their price target for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Canaccord Genuity Group raised their price target on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Finally, Morgan Stanley raised their price target on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $99.00.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the firm's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the firm's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.32% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.